Skip to main content Skip to navigation

AIRWAYS-3

hospital bed

AIRWAYS-3: Randomised trial of a supraglottic airway device versus tracheal intubation during in-hospital cardiac arrest

The trial is currently in setup.

LATEST NEWS

November 2022 - HRA Approval received and sites starting set up

October 2022 - Site Staff - Live Webinars - Register now!

MANDATORY TRAINING AND TRAINING LOG MUST BE COMPLETED BY ALL SITE STAFF - AIRWAYS-3 Training

**Anaesthetic trainee interested in research?**

- contact the CTU Trial Team airways3@warwick.ac.uk

Trial Design

This is a multi-centre, open-label, pragmatic, individually randomised, parallel group, superiority trial and economic evaluation to determine the clinical and cost effectiveness of SGA versus TI during IHCA. The trial will be conducted in the acute setting in NHS hospitals throughout the UK.

An internal pilot study will confirm the feasibility of the trial. An integrated economic evaluation will assess the cost-effectiveness of SGA compared with TI.

The primary outcome is the Modified Rankin Scale (mRS) score assessed at hospital discharge or 30 days following IHCA, whichever occurs sooner.

Read more

Chief Investigator: Professor Jonathan Benger

Sponsor: University Hospitals Bristol and Weston NHS Foundation Trust

Funder: National Institute for Health Research

Registration Number: ISRCTN17720457

Summary: Randomised trial of the clinical and cost effectiveness of a supraglottic airway device versus intubation during in-hospital cardiac arrest (Airways3)

The best way to keep a person’s airway open during a cardiac arrest has been thought to be placing a breathing tube in the windpipe (tracheal intubation). However, attempting to place a breathing tube can cause complications such as accidental placement in the oesophagus (food pipe) rather than the airway, tissue damage and interruptions in chest compressions.

It is possible that a newer method of airway management, inserting a supraglottic airway device, is better than tracheal intubation during cardiac arrest. Supraglottic airway devices are already used during routine anaesthesia in hospital; in emergency care, they are quicker to insert and cause less interruption to chest compressions.

Sample size:

4190 participants

Primary outcome:

Functional status at hospital discharge (or 30 days post-randomisation whichever is shorter) as measured by the modified Rankin Scale (mRS).

Duration:

1st January 2022 – 31st December 2026

Airways3

Sites in set up

Contact Trial Team

Email:

airways3@warwick.ac.uk

Address:

AIRWAYS-3 Trial Team
Warwick Clinical Trials Unit,
Warwick Medical School,
University of Warwick,
Coventry.
CV4 7AL

CTU Trial Team Members

Trial Manager - Chloe Norman

Trial Co-ordinator - Loraine Chowdhury

Trial Co-ordinator - Jannat Chowdhury

Data Entry Clerk - Laurilee Sprauve

NIHR

Bristol Hospitals

Warwick CTU logo